KRAS mutations in endometrial cancers: Possible prognostic and treatment implications
Open Access
- 4 November 2024
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 191, 299-306
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies2023
- A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapyCancer Cell, 2022
- KRAS ‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancerCancer Communications, 2022
- KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyondCancer Treatment Reviews, 2021
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyThe Lancet Oncology, 2020
- Mechanisms of immune escape in the cancer immune cycleInternational Immunopharmacology, 2020
- Enhancing anticancer activity of checkpoint immunotherapy by targeting RASMedcomm, 2020
- Mutant KRAS at the Heart of Tumor Immune EvasionImmunity, 2020
- Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNAImmunity, 2017
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patientsBritish Journal of Cancer, 2014